

Deutsche Bank – German & Austrian Corporate Conference 2011




Frankfurt – May 20, 2011

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

MorphoSys at a Glance



Technology

Industry's most successful antibody library technology - HuCAL




Pipeline

74 drug programs ongoing



Financial


Profitable, strong balance sheet




Use proprietary technologies to develop the broadest possible pipeline of therapeutic antibody drugs,

balanced between partnered and proprietary programs

Growing Pipeline Illustrates Successful Execution of Strategy



Unique & Proprietary Technology for Generating Drug-Quality Antibodies



74 Therapeutic Antibody Programs Ongoing: 18 Programs in Clinical Trials

Program (Partner)	Indication	Discovery	Pre-clinic	Phase 1	Phase 2	Phase 3	Market
MOR103, MorphoSys	Rheumatoid Arthritis						
n.d., Novartis	n.d.						
CNTO888, Centocor/J&J (2 Programs)	Cancer/IPF						
Gantenerumab, Roche	Alzheimer's Disease						
BHQ880, Novartis	Cancer						
MOR208, MorphoSys	Cancer						
CNTO 1959, Centocor/J&J	Psoriasis						
CNTO 3157, Centocor/J&J	Asthma						
n.d., Centocor Ortho Biotech	n.d.						
BAY79-4620, Bayer Schering	Cancer (ADC)						
n.d., Novartis (3 Programs)	n.d.						
n.d., Boehringer Ingelheim	n.d.						
n.d., Pfizer	n.d.						
OMP-59R5, Oncomed	Cancer						
OMP-18R5, Oncomed	Cancer						
MOR202, MorphoSys	Cancer						
20 Partnered Programs	Various Indications						
29 Partnered Programs	Various Indications						
6 Proprietary Programs (including 2 Co-Development Programs with Novartis)	Cancer & Inflammation						

65 Partnered Programs
9 Proprietary Programs




n.d. not disclosed

IPF: Idiopathic Pulmonary Fibrosis

ADC: Antibody Drug Conjugate

Current Pipeline

Projected HuCAL Drugs on the Market



Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development



MOR103

A Novel Anti-Inflammatory Antibody

The Target

- GM-CSF – a growth factor and inflammatory mediator

The Drug

- Ultra-high affinity HuCAL IgG1

Clinical Development in Rheumatoid Arthritis


- Phase 1b/2a trial ongoing in Europe in patients with active RA
- Completion of enrollment H2 2011, final results H1 2012

Clinical Development in Multiple Sclerosis

- Phase 1b safety study in MS patients starting H2 2011

Intellectual Property

- Exclusive license to a US patent covering antibodies against GM-CSF for the treatment of chronic inflammatory conditions
- US patent on MOR103 composition of matter



MOR208

A Novel Anti-Cancer Antibody

The Target



- CD19 – a pan B-cell marker

The Drug

- Humanized, high affinity anti-CD19 antibody
- Exclusive license from Xencor
- Comprises a proprietary Xencor modification that leads to rapid and sustained B-cell depletion

Clinical Development in Chronic Lymphocytic Leukemia

- Multi-centre, open-label, multi-dose, single-arm phase 1, dose-escalation study in USA
- Patients with chronic lymphocytic leukemia, who have not responded to or have become refractory to previous therapies
- Xencor funds phase 1 trial from \$13m up-front payment
- Final data expected in 2012



A Novel Antibody for Multiple Myeloma

The Target


- CD38 – a protein on multiple myeloma cells

The Drug

- High affinity HuCAL antibody
- Excellent cross-reactivity to non-human primate (tox)

Clinical Development in Multiple Myeloma

- Start multi-centre, open-label, dose-escalation study in Europe H1 2011
- Patients with relapsed/refractory multiple myeloma; failure of at least 2 prior therapies
- Maximum tolerated dose, safety and tolerability, pharmacokinetics and immunogenicity; assessment of preliminary activity
- Final data expected in 2013



AbD Serotec Segment Complements Therapeutic Business

Antibodies for research and diagnostic markets

Diagnostic Antibodies

- Using proprietary technologies to deliver superior Dx antibodies
- Future upside via royalties

Research Antibodies

- Catalogue of 15,000+ products & custom HuCAL antibodies
- Stable and recurring cash flows

EUR millions	Guidance 2011	2010
AbD Serotec Segment Revenues	22 - 23	20.2
AbD Serotec Profit Margin	~ 4%	6%



P&L and Guidance 2011

EUR millions	2010	Q1 2011	Guidance 2011
Revenues	87.0	48.6	105 – 110
Total Operating Expenses	77.4	19.9	
Other Operating Income	0.2	0.1	
Profit from Operations	9.8	28.8	10 – 13

- Investment in Proprietary R&D will amount to EUR 40-45 million (2010: EUR 26.3 million)




Balance Sheet and Shareholder Structure

Balance Sheet

EUR millions	March 31, 2011	Dec. 31, 2010
Assets		
Cash, Cash Equivalents & Marketable Securities	119.8	108.4
Other Current Assets	47.9	24.1
Total Non-Current Assets	79.0	80.0
Total Assets	246.7	212.6
Liabilities		
Total Current Liabilities	30.3	21.4
Total Non-Current Liabilities	10.6	5.3
Total Shareholders' Equity	205.8	185.9
Total Liabilities	246.7	212.6



Shareholdings by Investor Type



Shares issued: 22,890,252 (Dec 31, 2010)



Dr. Simon E. Moroney, CEO

- Co-founder; prior positions: University of Cambridge/UK, University of British Columbia/Canada, ETH Zurich/CH, ImmunoGen Inc., Associate in the Harvard Medical School, Boston/USA
- Commonwealth Scholar to the University of Oxford – D. Phil. 1984
- German Cross of the Order of Merit (2002), Bavarian State Medal for Outstanding Services to the Bavarian Economy (2009)



Jens Holstein, CFO

- Joined MorphoSys in 2011 from Fresenius Kabi
- Prior positions: Regional CFO for the region EME of Fresenius Kabi AG; variety of financial and general management positions at Fresenius
- Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry (Frankfurt and London)
- Mr. Holstein holds a Diploma in Business Administration from University of Münster.



Dr. Arndt Schottelius, CDO

- Joined MorphoSys in 2008 from Genentech Inc., SF, position: Medical Director, Immunology Development
- Prior positions: Berlex Biosciences, USA; Schering, Germany; Charité University Hospital, Berlin
- PhD and MD degrees from the Albert-Ludwigs-University, Freiburg/Germany
- Medical studies in Germany, UK and Switzerland



Dr. Marlies Sproll, CSO

- Joined MorphoSys in 2000 as R&D department head, promoted to CSO in 2005
- Prior positions: Vienna research facility of Boehringer Ingelheim, lab leader at Merck KGaA in Darmstadt/Germany, involved in preclinical development of therapeutic antibodies
- Ph.D. from the Max Planck Institute in Tübingen/Germany, Doctor of Natural Science by the University of Stuttgart

A Rich Potential Newsflow in 2011



- US patent granted on MOR103 ✓
- Double digit EUR million technology milestone received from Novartis ✓
- MOR202
 - Publish MOR202 pre-clinical data at ASCO
 - Start Phase 1 study in multiple myeloma patients
- MOR103
 - Complete enrollment of Phase 1b/2a rheumatoid arthritis study
 - Start Phase 1b in multiple sclerosis patients
- 1–3 partner INDs (✓)
- Data from ongoing trials of partnered programs



- First diagnostic kit based on a HuCAL antibody will be launched ✓



- Further technology announcements
- New deal(s) based on Slonomics technology

Thank You



www.morphosys.com

Dr. Simon Moroney
Chief Executive Officer

Phone +49 (0)89 / 899 27-311
Fax +49 (0)89 / 899 27-5311

Dr. Claudia Gutjahr-Löser
Head of Corporate Comm. & IR

Phone +49 (0)89 / 899 27-122
Fax +49 (0)89 / 899 27-5122
Email investors@morphosys.com